CARVER, Mass. & NUREMBERG, Germany--(BUSINESS WIRE)--Decas Botanical Synergies, LLC (DBS) today announced the results of the recently completed clinical study titled, “A randomized double blind placebo controlled trial to evaluate the efficacy of cranberry powder as a prophylactic against recurrent urinary tract infection (UTI) in women” (Vidlar, et. al.). These results were presented at the 15th annual PhytoPharm Congress 2011 in Nuremberg, Germany July 25 through 27, 2011. The aim of this 6 month intervention trial was to assess the efficacy of a daily dose of 500 mg of PACran® in women with a history of recurrent UTIs. The results of the study showed 22 recurrent UTIs in the placebo group with only 11 recurrent UTIs in the cranberry group. The recurrence rate for the cranberry group was 14.2%, corresponding to an absolute reduction in UTI recurrence of 15%. While the recurrence rate for the placebo group was 25.7%, corresponding to an assumed 30% recurrence rate in the placebo group. These data further validate that a 500 mg daily dose of PACran is effective at supporting urinary tract health.
